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MMP-3 is capable of degrading a variety of proteins, including agrin, which plays a critical role in neuromuscular signaling by
controlling acetylcholine receptor clustering. High MMP-3 levels in a proportion of myasthenia gravis (MG) patients have been
reported. A pathogenic role of MMP-3 in other neurological disorders has been suggested but not proven. We have therefore
examined the levels of MMP-3 in 124 MG patients and compared them to 59 multiple sclerosis (MS) patients, 74 epilepsy patients,
33 acute stroke patients, and 90 healthy controls. 15.3% of the patients in the MG group were MMP-3-positive (deﬁned as higher
than cutoﬀ value 48ng/mL) with very high mean MMP-3 concentration (79.9ng/mL), whereas the proportion of MMP-3 positive
patients in the MS (3.4%), epilepsy (6.7%), stroke (0%), and the control group (4.4%) was signiﬁcantly lower. Mean MMP-3
concentration in the total MG group (25.5ng/mL) was signiﬁcantly higher than in the MS (16.6ng/mL) and stroke (11.7ng/mL)
groups, but did not diﬀer signiﬁcantly from the epilepsy (19.4ng/mL) and the control group (23.4ng/mL). MMP-3 may have a
speciﬁc pathogenic eﬀect in MG in addition to being associated with autoimmune diseases in general.
1.Introduction
Matrix metalloproteinase-3 (MMP-3) is a matrix enzyme
capable of breaking down various extracellular components,
including collagens (types III, IV, V, IX, and XI), matrix
proteins, and proteoglycans. MMP-3 can also activate other
MMPs such as MMP-9 [1, 2]. Agrin is a substrate for the
endopeptidase MMP-3, stromelysin1 [3]. MMP-3 null mice
have alterations to their neuromuscular junctions, including
increased acetylcholine receptor (AChR) staining at the
endplate and an increased number of junctional folds. An
increased concentration of agrin occurs at the neuromuscu-
lar junction of such mice [4]. These observations indicate
that MMP-3 is involved in controlling the structure of the
neuromuscular junction via regulation of agrin levels.
Myasthenia gravis (MG) is an autoimmune disorder
which causes skeletal muscle weakness. Antibodies targeting
the AChR are present in 85% of patients with gener-
alized MG (GMG) and in about 50% of patients with
ocular MG (OMG) [5, 6]. MG with AChR antibodies is
known as seropositive MG (SPMG). Thymoma is present
in approximately 15% of MG patients [7]. Antibodies to
AChR impair neuromuscular transmission by complement-
mediated postsynaptic membrane damage, direct blockade
of ligand-receptor interaction, and/or by an increased degra-
dation of AChR [5, 8]. MG without detectable antibodies
to the AChR is termed seronegative MG (SNMG) [9].
Antibodies to muscle-speciﬁc kinase (MuSK) are observed
in a proportion of SNMG patients [10, 11]. MuSK is a
key signaling protein controlling AChR clustering and the
formation of the neuromuscular junction. These processes
are triggered by the release of agrin from the nerve terminals.
AgrininteractionwithMuSKleadstothephosphorylationof
AChR [12, 13].
Elevated serum MMP-3 levels have previously been
reported in the autoimmune disorders systemic lupus ery-
thematosus (SLE) and rheumatoid arthritis (RA) [14, 15].
A pathogenic role of MMP-3 in these connective tissue dis-
orders could be related to its ability to degrade extracellular
matrixcomponents.SLEandRAhaveanincreasedincidence2 Autoimmune Diseases
in MG patients [16, 17], indicating shared pathogenic
mechanisms. These disorders are associated with localized
autoimmune diseases such as Hashimoto’s thyroiditis and
Graves’ disease [18].
In MG patients, an elevated MMP-3 level, in addition
to promoting autoimmune disease in general, may cause
damage to the neuromuscular junction due to increased
degradation of agrin, and thereby contribute to an increased
muscle weakness. In a previous study [19], we demonstrated
a signiﬁcant elevation in MMP-3 levels in a proportion of
both SPMG and SNMG, indicating a pathogenic role for
MMP-3 in MG. Little is known about MMP-3 in other
autoimmune and nonautoimmune neurological disorders.
WehavethereforeexaminedthelevelsofMMP-3inserafrom
MG patients and compared them to those in multiple sclero-
sis(MS)patients,epilepsypatients,acutestrokepatients,and
healthy controls.
2.MaterialsandMethods
2.1. Patients and Sera. Serum samples from 124 MG patients
(104 SPMG and 20 SNMG), 59 MS patients, 74 epilepsy
patients, 33 acute stroke patients, and 90 healthy controls
available in our biobank, taken from diﬀerent individuals,
were included (Table 1). The MG and MS sera were collected
randomly at various disease phases from in and outpatients
admitted to our department. The sera from the epilepsy
patients and the acute stroke patients were obtained within
24 hours after last seizure or acute stroke, respectively, from
inpatients admitted to our department. The MG group
included patients with early-onset MG (MG onset before
age 50 years), late-onset MG (MG onset at or after age 50
years), thymoma MG and nonthymoma MG, and patients
with various antibodies including antiAChR, antiryanodine
receptor and antititin antibodies, but none with MuSK
antibodies. None of the patients had any confounding
diseases, such as SLE or RA. The control sera were collected
randomly from healthy individuals. All sera were stored at
−20◦C.
2.2. Serum MMP-3 Levels. Total MMP-3 levels were assessed
using the Quantikine MMP-3 Elisa kit as per manufacturer’s
instructions (R&D Systems Europe Ltd. Abingdon, UK).
Patient sera were assayed at a dilution of 1:10 in duplicate
wells. A standard curve (0.156ng/mL–20ng/mL MMP-
3) was produced and the MMP-3 concentration (ng/mL)
determined.
The cut-oﬀ l e v e lb e t w e e nan o r m a la n dah i g hM M P - 3
level (hereafter referred to as MMP-3-positive) was deﬁned
as the mean MMP-3 concentration for the 90 controls + 2
SDs, which equals 48ng/mL (Figure 1).
2.3. Statistical Analyses. The numbers of patients in the
various groups were compared using the Chi-square test.
The MMP-3 concentrations in the diﬀerent groups were
compared using the t-test for diﬀerence between population
means.
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Figure 1:ScatterplotoftheMMP-3concentrationsinpatientswith
neurological disorders and healthy controls. The 2 SD cut-oﬀ at
48ng/mL is indicated.
3. Results
Nineteen (15.3%) MG patients were MMP-3-positive,
whereas the numbers of MMP-3-positive patients in the MS,
epilepsy and control groups were very low (3%, 6%, and 4%,
resp.). There were no MMP-3-positive patients in the acute
stroke group (Table 1, Figure 1). The number of MMP-3-
positive patients in the MG group was signiﬁcantly higher
than the number of MMP-3-positive patients in the MS
group (P = 0.034), the acute stroke group (P = 0.036), and
the control group (P = 0.021), but did not reach signiﬁcance
for the epilepsy group (P = 0.118) (Table 1).
The MG group had the highest mean MMP-3 concen-
tration. It was signiﬁcantly higher than the mean MMP-3
concentration in the MS group (P = 0.013), the epilepsy
group (P = 0.026), and the acute stroke group (P<0.001),
but did not diﬀer signiﬁcantly from that in the control
group (P = 0.225) (Table 1). Mean MMP-3 concentration
of the 19 MMP-3-positive MG patients was signiﬁcantly
higher than mean MMP-3 concentration in the total MG
group (P<0.001) and in the total control group (P<
0.001). Mean MMP-3 concentration of the 19 MMP-3-
positive MG patients was also signiﬁcantly higher than mean
MMP-3 concentration of the four MMP-3-positive controls
(P = 0.001) but did not diﬀer signiﬁcantly from mean
concentration of the ﬁve MMP-3-positive epilepsy patients
(P = 0.148) (Table 1). Mean MMP-3 concentration was
lowest in the acute stroke group. It was signiﬁcantly lower
than mean MMP-3 concentration in the MG group (P<
0.001),theepilepsygroup(P<0.001),andthecontrolgroup
(P<0.001)andtendedtobelowerthanthatintheMSgroup
(P = 0.078)(Table 1).TheMSgrouphadsigniﬁcantlyhigher
mean MMP-3 concentration than the controls (P = 0.024),
in contrast to the epilepsy group that had lower mean MMP-
3 than the controls (P = 0.042) (Table 1).
4. Discussion
A proportion of MG patients (15.3%) had markedly
increased MMP-3 levels. This was unique as compared to
patients with other neurological disorders in this study.
Similarly, the mean MMP-3 concentration in the MG group
was increased. In a previous study [19], we demonstratedAutoimmune Diseases 3
Table 1: MMP-3 concentrations (ng/mL) in patients with neurological disorders and healthy controls.
MG MS Epilepsy Stroke Healthy controls
Number of patients 124 59 74 33 90
Mean MMP-3 concentration 25.5 (±27.4) 16.6 (±23.9) 19.4 (±16.4) 11.7 (±8.1) 23.4 (±12.3)
Number of MMP-3-positives 19 (15.3%) 2 (3.4%) 5 (6.7%) 0 4 (4.4%)
Mean MMP-3 concentration of MMP-3-positives 79.9 (±27.9) 116.5 (±89.8) 67.0 (±21.2) 0 54.0 (±3.6)
that elevated MMP-3 levels are present in both SPMG and
SNMG and thus is linked to MG in general.
MMP-3-positive MG patients exhibited high mean
MMP-3 concentrations (79.9ng/mL) compared to the whole
MG group (25.5ng/mL) and controls (23.4ng/mL), indicat-
ing that these patients represent a subgroup with diﬀerences
in pathophysiology and/or clinical presentation. Our cohort
comprised patients at diﬀerent age, gender, disease severity,
and disease types (SPMG, SNMG, early-onset MG, late-
onsetMG,thymomaMG,andnonthymomaMG).Itwasnot
possible to correlate MMP-3-positive patients with a speciﬁc
subset of MG patients, perhaps due to low number of MMP-
3-positive MG patients and large variation in disease entities.
A similar subgroup with high MMP-3 levels in another
MG cohort was recently reported, containing GMG, OMG,
SPMG, and SNMG patients [20].
None of our acute stroke patients had elevated MMP-
3 levels, and mean MMP-3 concentration was lower than
in any other group examined. MMP-3 may play a role in
the pathophysiology of acute stroke [21]. Thromboembolic
mechanisms and MMP-3 consumption may be the cause of
the low MMP-3 concentrations seen in acute stroke.
In an earlier study, Kanesaka et al. found elevated MMP-
3 levels during the relapsing phase of relapsing-remitting
MS compared to the remission phase [22]. In our study,
MS and MG patients were included regardless of disease
phase or severity. This may explain the discrepancy between
our results and those of Kanesaka et al. Our conclusion
is that MG patients have higher MMP-3 levels than MS
patients when disease phase and severity are not taken into
consideration.
Very high mean MMP-3 concentrations of 258 ±
35ng/mLand187 ±14ng/mLhavepreviouslybeenreported
in SLE and RA patients, markedly higher than in our MG
patients [14]. However, mean serum MMP-3 concentration
in our control group is approximately half that observed
for the controls in that previous study. Methodological
variation may therefore explain this diﬀerence between MG
and SLE/RA. Serum levels of MMP-3 may not represent the
concentrationofMMP-3atthesite(s)oftissuedamage,since
MMP-3 can be produced locally and there have a concentra-
tion higher than observed in the general circulation. Serum
MMP-3 levels may be higher in systemic diseases such as SLE
and RA compared to MG with more focal damage.
Since agrin is required for the clustering of AChR in the
neuromuscular junction, increased degradation of agrin and
subsequent disruption of MuSK signaling, may have impor-
tant consequences for the correct formation and function
of the neuromuscular junction and lead to a reduction in
the safety factor for successful neuromuscular transmission.
Agrin is also capable of inducing the expression of the 
subunit of the AChR [23, 24]. MMP-3 null mice show
alterations to their neuromuscular junctions [4], probably
via an eﬀect on agrin.
An increased MMP-3 level as a cause of MG is unlikely,
since MMP-3 levels are increased in patients with SLE and
RA who do not have MG [14, 15]. The mechanism by which
MMP-3 is upregulated and the signiﬁcance of an increased
level of MMP-3 in MG, SLE, and RA is unknown. By
expanding our patient database, we hope to identify clinical
or immunological associations with the observed increase in
MMP-3, further elucidating mechanisms and signiﬁcance.
Some MG patients have high MMP-3 serum concen-
trations, and this may reﬂect a subgroup with diﬀer-
ent pathophysiology and/or diﬀerent clinical presentation.
Dysregulation of MMP-3 could be a common feature of
autoimmune diseases, including MG, SLE, and RA, but not
MS as examined in this study. The mechanism(s) by which
altered MMP-3 levels in MG and acute stroke occurs, and
its pathological signiﬁcance remain to be established. MMP-
3 testing might be useful as an indicator of acute cerebral
ischemia in its very early phase.
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